CHMP recommends for approval generic version of Prezista

November 11, 2016

At its November meeting, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended for approval a generic version of Prezista – Darunavir Mylan (darunavir) for the treatment of HIV infection.

Summary of opinion for Darunavir Mylan is available here.

Original Article

Post Views: 652

Single zoledronic acid infusion slows early bone loss in individuals starting HIV treatment

Brochure: The European regulatory system for medicines

CHMP recommends for approval generic version of Prezista

Related News

Behavioral intervention reduces HIV transmission risk in young transgender women

Global progress towards hepatitis C elimination still blocked by cost of treatment, lack of diagnosis

Vladimir Zhovtyak: European AIDS conference is a step forward to control the HIV/AIDS in Europe

Patient Communities Agree on Shared Vision of HIV Treatment Regimen

Glecaprevir/pibrentasvir is effective for people with HIV/HCV co-infection